Test medicines for motor neurone disease using adaptive trial design
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests treatments for motor neurone disease (MND) and assigns people to different treatment arms in an adaptive way. It may help doctors find out which medicine works best and for whom.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a confirmed MND diagnosis (including ALS, primary lateral sclerosis, or progressive muscular atrophy)
- If you can become pregnant (and fertile men), you must use effective contraception and follow the pregnancy-test rule
- You are willing and able to follow the study plan and answer questionnaires
- You must be able to give informed consent (with witness support if needed due to limb problems)
- You do not have conditions that prevent safe participation (for example, certain severe mental health issues, active suicide thoughts, or pregnancy/breast-feeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining non-invasive brain stimulation (a gentle, non-surgical treatment) with exercise can help people with motor neuron disease (MND). It may improve movement and quality of life for those with mild to moderate symptoms.
This study looks at how your body uses energy and nutrients when you have motor neurone disease (MND). It focuses on people who are starting to see a specialist breathing clinic, to better understand nutrition and metabolism in MND.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
Hear when a new Motor Neuron Disease, Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.